SCHEMBL22985891

SCHEMBL22985891

COc1cc(C(O)N2CCC(N3CCOCC3)CC2)ccc1Nc1nc(NC(C)(C)C)c2c(Cl)c[nH]c2n1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 5/20 0.53
▸ ALK Q9UM73 5/20 0.44
▸ DYRK1A Q13627 4/20 0.43
▸ TTK P33981 3/20 0.43
▸ INSR P06213 2/20 0.42
▸ IGF1R P08069 1/20 0.42
▸ DYRK3 O43781 1/20 0.42
▸ CSNK1E P49674 1/20 0.42
▸ CLK1 P49759 1/20 0.42
▸ CLK2 P49760 1/20 0.42
▸ CLK3 P49761 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ DYRK1B Q9Y463 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ PTK2 Q05397 1/20 0.41
▸ EGFR P00533 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22985886 0.90 LRRK2 (0.54) LRRK2ALKDYRK1ATTKINSR
SCHEMBL22985862 0.88 LRRK2 (0.65) LRRK2ALKDYRK1ATTKINSR
SCHEMBL22985920 0.87 LRRK2 (0.52) LRRK2ALKDYRK1ATTKINSR
SCHEMBL22985869 0.87 DYRK1A (0.52) LRRK2ALKDYRK1ATTKINSR
SCHEMBL22985894 0.87 DYRK1A (0.52) LRRK2ALKDYRK1ATTKINSR
SCHEMBL22985863 0.85 ALK (0.63) LRRK2ALKDYRK1ATTKINSR
SCHEMBL18018968 0.84 LRRK2 (0.74) LRRK2DYRK1ATTKDYRK3CSNK1E
SCHEMBL18018932 0.75 LRRK2 (0.88) LRRK2DYRK1ATTKDYRK3CSNK1E
SCHEMBL18018966 0.75 LRRK2 (0.74) LRRK2DYRK1ATTKDYRK3CSNK1E
SCHEMBL22985871 0.75 LRRK2 (0.75) LRRK2DYRK1ATTKDYRK3CSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3778605-A2 LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME Dana Farber Cancer Institute, Inc. (US) 2021-02-17 — — EP disclosed
EP-3778604-A1 LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME Dana Farber Cancer Institute, Inc. (US) 2021-02-17 — — EP disclosed
Send feedback